HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neng-Yao Shih Selected Research

Phosphopyruvate Hydratase (Enolase)

1/2017In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically.
10/2015Anti-α-enolase is a prognostic marker in postoperative lung cancer patients.
5/2015Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.
1/2013Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target.
10/2011Overexpression of α-enolase correlates with poor survival in canine mammary carcinoma.
10/2010Generation and characterization of anti-alpha-enolase single-chain antibodies in chicken.
10/2010MBP-1 is efficiently encoded by an alternative transcript of the ENO1 gene but post-translationally regulated by proteasome-dependent protein turnover.
7/2010Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
6/2010Increased expression of enolase alpha in human breast cancer confers tamoxifen resistance in human breast cancer cells.
10/2006Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Neng-Yao Shih Research Topics

Disease

15Neoplasms (Cancer)
01/2019 - 10/2006
7Lung Neoplasms (Lung Cancer)
01/2019 - 10/2006
4Disease Progression
11/2018 - 08/2007
3Neoplasm Metastasis (Metastasis)
01/2019 - 01/2013
3Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
11/2018 - 01/2013
3Breast Neoplasms (Breast Cancer)
10/2011 - 06/2010
2Carcinogenesis
01/2019 - 10/2010
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
11/2018 - 10/2016
2Adenocarcinoma of Lung
05/2016 - 05/2009
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/2015 - 07/2010
2Inflammation (Inflammations)
07/2010 - 05/2009
2Malignant Pleural Effusion
08/2007 - 10/2006
1Ovarian Neoplasms (Ovarian Cancer)
01/2019
1Hypoxia (Hypoxemia)
01/2017
1Myeloid Leukemia (Leukemia, Myelocytic)
10/2016
1Pancreatic Neoplasms (Pancreatic Cancer)
05/2015
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2015
1Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
01/2015
1Lymphoma (Lymphomas)
01/2015
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2015
1Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
01/2015
1Carcinoma (Carcinomatosis)
10/2011
1Neurodegenerative Diseases (Neurodegenerative Disease)
02/2011
1Infections
12/2010
1Small Cell Lung Carcinoma (Small Cell Lung Cancer)
07/2010
1Head and Neck Neoplasms (Head and Neck Cancer)
06/2010
1Atherosclerosis
01/2009
1Thrombosis (Thrombus)
01/2009

Drug/Important Bio-Agent (IBA)

10Phosphopyruvate Hydratase (Enolase)IBA
01/2017 - 10/2006
5Proteins (Proteins, Gene)FDA Link
01/2019 - 10/2010
4EnzymesIBA
01/2019 - 06/2010
4Small Interfering RNA (siRNA)IBA
08/2014 - 05/2009
3AntigensIBA
01/2019 - 10/2006
3Imatinib Mesylate (Gleevec)FDA Link
11/2018 - 01/2013
3AntibodiesIBA
10/2015 - 10/2006
3Messenger RNA (mRNA)IBA
08/2014 - 06/2010
2GTP-Binding Proteins (G-Protein)IBA
01/2019 - 05/2016
2Phosphotransferases (Kinase)IBA
01/2019 - 11/2018
2Biomarkers (Surrogate Marker)IBA
01/2019 - 01/2019
2Tyrosine Kinase InhibitorsIBA
10/2016 - 01/2013
2PlasminogenIBA
05/2015 - 01/2013
1SuspensionsIBA
01/2019
1Member 2 Subfamily G ATP Binding Cassette TransporterIBA
01/2019
1Adenosine Triphosphate (ATP)IBA
01/2019
1Cisplatin (Platino)FDA LinkGeneric
01/2019
1ImmunosorbentsIBA
01/2019
1Nucleic AcidsIBA
01/2019
1SaltsIBA
01/2019
1Paclitaxel (Taxol)FDA LinkGeneric
01/2019
1Pharmaceutical PreparationsIBA
01/2017
1Glucose (Dextrose)FDA LinkGeneric
01/2017
1Core Binding Factors (Core-Binding Factor)IBA
10/2016
1Complementary DNA (cDNA)IBA
05/2015
1FibrinolysinFDA Link
05/2015
1Serine Proteases (Serine Protease)IBA
05/2015
17-hydroxy-6-methoxyphthalide (MA-1)IBA
01/2015
15- (2,4- dihydroxy- 5- isopropylphenyl)- 4- (4- morpholin- 4- ylmethylphenyl)isoxazole- 3- carboxylic acid ethylamideIBA
01/2015
1Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2013
1Urokinase Plasminogen Activator ReceptorsIBA
01/2013
1Estrogens (Estrogen)FDA Link
10/2011
1LithiumIBA
02/2011
1Carbapenems (Carbapenem Antibiotics)IBA
12/2010
1IgYIBA
10/2010
1GoldIBA
07/2010
1AutoantibodiesIBA
07/2010
1Immunoglobulin A (IgA)IBA
07/2010
1Immunoglobulin G (IgG)IBA
07/2010
1Immunoglobulin M (IgM)IBA
07/2010
1Immunoglobulins (Immunoglobulin)IBA
07/2010
1Chemokine CCL20IBA
06/2010
1afimoxifene (hydroxytamoxifen)IBA
06/2010
1TamoxifenFDA LinkGeneric
06/2010
1Estrogen ReceptorsIBA
06/2010
14,17 beta-dihydroxy-4-androstene-3-oneIBA
06/2010
1ChemokinesIBA
05/2009
1VaccinesIBA
05/2009
1ClusterinIBA
05/2009
1Cadherins (E-Cadherin)IBA
05/2009
1Fibronectins (Fibronectin)IBA
05/2009
1Cancer VaccinesIBA
05/2009
1Ticlopidine (Ticlid)FDA LinkGeneric
01/2009
1Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
01/2009
1Alanine (L-Alanine)FDA Link
08/2007
1Transforming Growth Factor-beta Type I ReceptorIBA
08/2007
1Protein Sorting Signals (Signal Peptide)IBA
08/2007
1Transforming Growth Factor beta (TGF-beta)IBA
08/2007
1AutoantigensIBA
10/2006

Therapy/Procedure

3Therapeutics
01/2015 - 06/2010
1Lasers (Laser)
06/2010